
    
      Sipuleucel-T will be administered as standard of care. Oral Indoximod/placebo will be
      self-administered twice daily for 6 months starting after the last infusion of sipuleucel-T.
      Patients will be treated for a minimum of 12 weeks of Indoximod/placebo before disease
      progression can be declared and Indoximod/placebo will not be discontinued for increasing
      prostate specific antigen (PSA) in the absence of symptomatic clinical progression.
    
  